Right Heart Catheterization — Clinical Applications
Definition
The same six measurements serve every context, but what counts as actionable changes with the disease. In chronic heart failure the question is whether filling pressures explain the syndrome; in cardiogenic shock it is which ventricle has failed and by how much; before transplantation and LVAD implantation it is whether the right ventricle can tolerate the circulation it is about to be given. This spoke sets out what each context asks of the catheter and where the answers are contested.
Key Concepts
Pulmonary Hypertension
- Confirmation is the indication. Catheterisation is required to confirm pulmonary hypertension and is mandatory before pulmonary arterial hypertension therapy begins; echocardiography assigns a probability but cannot confirm the diagnosis. The three-step suspicion, detection and confirmation pathway is on concepts/Pulmonary-Hypertension. (sources/PHT-ESC-2022, rating: very high)
- Suspected PH due to left heart disease: catheterisation is recommended when the result would change management, which is the group in which the 13–15 mmHg grey zone actually decides the label. (sources/PHT-ESC-2022)
- The catheter feeds risk stratification, not only diagnosis. The three-strata model at diagnosis takes right atrial pressure, cardiac index, stroke volume index and mixed venous saturation alongside functional class, walk distance and natriuretic peptide — see concepts/PAH-Risk-Stratification. (sources/PHT-ESC-2022)
- Repeat study belongs to reassessment, every 3–6 months and as clinically indicated; a full reassessment including catheterisation at 3–6 months is mandatory in one group, the vasoreactive patient started on calcium channel blockers.
- Only one finding changes immediate management: a positive acute vasoreactivity test. The protocol, doses and the rule against vasodilators when the wedge is raised are on concepts/RHC-Haemodynamic-Interpretation; what follows a positive test is on concepts/PAH-Treatment.
- The diagnosed threshold and the treated threshold are not the same. Pulmonary hypertension is defined at a mean pulmonary artery pressure above 20 mmHg with resistance above 2 WU, but every approved therapy was studied at 25 mmHg and 3 WU, so no efficacy data exist in the 21–24 mmHg band. The parent page records this in full. (sources/PHT-ESC-2022)
Chronic Heart Failure
- The haemodynamic phenotypes are defined by the pulmonary artery pressure, the wedge pressure, the right atrial pressure and the resistance together. Biventricular failure — the typical pattern — has a mean pulmonary artery pressure of 25–35 mmHg, wedge above 15, right atrial pressure above 8, resistance of 2–5 WU and mild-to-moderate right ventricular dysfunction. The right-heart-predominant pattern has a mean pressure above 35, right atrial pressure above 12, resistance above 5 WU (which may fall after diuresis), cardiac index below 2.2 L/min/m², severe tricuspid regurgitation and cardio-hepato-renal syndrome. (sources/rhc-hf-ehj-2025, rating: high)
- Constrictive pericarditis and restrictive cardiomyopathy both raise the right atrial to wedge ratio above 0.5 and are separated by their behaviour in inspiration — discordant in constriction, concordant in restriction, with diastolic flow reversal in the hepatic vein in restriction. Simultaneous right and left catheterisation is often needed, and cardiac magnetic resonance is the alternative when it is contraindicated. The criteria are on concepts/Constrictive-vs-Restrictive. (sources/rhc-hf-ehj-2025)
- Guideline positions differ. ESC gives Class 2a where heart failure is thought due to constrictive pericarditis, restrictive cardiomyopathy, congenital heart disease or a high-output state; Class 2b to confirm HFpEF in selected patients and for wireless pulmonary artery monitoring, where CHAMPION showed a 33% reduction in heart failure hospitalisation. AHA makes routine catheterisation Class 3, on the grounds that it does not provide enough information to guide treatment. (sources/rhc-hf-ehj-2025)
Acute Heart Failure
- The Diamond–Forrester classification (1973) divides patients by cardiac index (2.5 L/min/m²) and wedge pressure (18 mmHg) into warm or cold and wet or dry. It survives, although ESC 2021 prefers clinical phenotypes: acute decompensation, pulmonary oedema, isolated right ventricular failure and cardiogenic shock. (sources/rhc-hf-ehj-2025, rating: high)
| Phenotype | PAWP | CI | RAP | Blood pressure |
|---|---|---|---|---|
| Acute left ventricular failure | >15 mmHg | ≥2.5 L/min/m² (often maintained) | — | Maintained |
| Acute isolated right ventricular failure | <18 mmHg | <2.5 L/min/m² | >8 mmHg | Reduced |
| Acute biventricular failure | >15 mmHg | <2.5 L/min/m² | >8 mmHg | Reduced |
(sources/rhc-hf-ehj-2025, rating: high)
- The hallmark of biventricular failure is a right atrial to wedge ratio above 0.5.
- Read the table's boundaries with care: isolated right ventricular failure is defined against a wedge below 18 mmHg while biventricular failure is defined against a wedge above 15. A pressure of 16 mmHg with a raised right atrial pressure and a low index satisfies both rows.
Cardiogenic Shock
- The SCAI stages map onto haemodynamic bands. From Stage B to E the wedge pressure exceeds 15 mmHg, and in Stage E it exceeds 20. From Stage C onwards the index falls below 2.2 L/min/m² and right atrial pressure exceeds 10 mmHg. Mixed venous saturation is maintained at or above 65% in Stages A and B and falls from Stage C. (sources/rhc-hf-ehj-2025, rating: high)
- Isolated right ventricular shock: right atrial pressure above 14 mmHg, wedge normal or high-normal below 18, ratio above 0.5–0.8, a reduced pulmonary artery pulsatility index and an index below 2.2. In right ventricular infarction the ratio is at or above 0.8. (sources/rhc-hf-ehj-2025)
| Shock type | CI | PAWP | SVRI |
|---|---|---|---|
| Cardiogenic (cold and wet) | Low | High | High |
| Vasodilatory (warm and dry) | High | Normal | Low |
| Mixed | Variable | High | Normal or low |
- Advanced markers identify Stage C earlier than clinical assessment. A pulsatility index below 2.0 and cardiac power output below 0.6 W suggest Stage C. Right ventricular failure is signalled by a right atrial pressure above 15 mmHg, a ratio to wedge above 0.6, an index below 1.5 and right ventricular power output below 0.3 W, using mean pulmonary artery pressure in place of mean arterial pressure. (sources/rhc-hf-jacchf-2024, rating: high)
- Heart-failure cardiogenic shock is not acute myocardial infarction shock. In infarction, abrupt dysfunction produces rapid clinical deterioration that is obvious at the bedside. In progressive heart failure the low output is chronic and compensated, so the haemodynamic derangement can be more extreme while end-organ function and lactate remain normal. That is the reason catheterisation adds most value here: examination and biochemistry underestimate severity exactly where it is greatest. (sources/rhc-hf-jacchf-2024)
- Timing: early catheterisation within two days is associated with less acute kidney injury (odds ratio 0.69), more mechanical circulatory support (1.67) and shorter stay than late catheterisation, in an observational cohort of 46,963 patients. A randomised trial is running (NCT05485376). (sources/rhc-hf-ehj-2025)
Valvular Heart Disease
- Reserve the catheter for disagreement. ESC limits it to inconclusive or discordant non-invasive assessment, and requires confirmation when a systolic pulmonary artery pressure above 50 mmHg is the only surgical criterion. (sources/rhc-hf-ehj-2025, rating: high)
- Severe tricuspid regurgitation makes Doppler gradients underestimate pulmonary hypertension, so catheterisation with resistance measurement is recommended. (sources/rhc-hf-ehj-2025)
- Severe primary mitral regurgitation: catheterise to confirm pulmonary hypertension when that is the sole reason for surgical referral. (sources/rhc-hf-ehj-2025)
- Mitral stenosis: AHA gives catheterisation Class 1 at rest and during exercise, with direct pressure gradient measurement when imaging is inadequate. (sources/rhc-hf-ehj-2025)
- Aortic stenosis: catheterisation is the gold standard for diagnosing pulmonary hypertension, which is a strong mortality predictor in severe disease and adds prognostic power to echocardiography alone. See concepts/Aortic-Stenosis. (sources/rhc-hf-ehj-2025)
Heart Transplantation
- Before listing (ISHLT Class 1), catheterisation is required and repeated every 3–6 months until transplantation. A wedge pressure above 18 mmHg is independently associated with waitlist death, delisting, urgent transplantation and LVAD implantation in a French registry of 837 patients, and a resistance above 2.5 WU with increased post-transplant mortality in 26,649 patients. (sources/rhc-hf-ehj-2025, rating: high)
- Prohibitive pulmonary hypertension triggers a vasodilator challenge. The thresholds and the acceptable response are paired below.
| Parameter | Prohibitive — triggers challenge | Acceptable after challenge |
|---|---|---|
| Systolic pulmonary artery pressure | ≥50 mmHg | — |
| Transpulmonary gradient | ≥15 mmHg | ≤12–15 mmHg |
| Pulmonary vascular resistance | ≥3 WU | ≤2.5–3 WU |
| Systolic blood pressure | — | >85 mmHg |
(sources/rhc-hf-ehj-2025, rating: high)
- Reversible resistance with a systolic pressure that stays below 85 mmHg still carries a high risk of right ventricular failure after transplantation. A failed challenge leads to hospitalisation, diuresis, temporary mechanical support and then durable LVAD; an LVAD can reverse the pulmonary hypertension, and resistance persisting after 3–6 months of effective unloading is treated as irreversible.
- After transplantation, Grade 3 cardiac allograft vasculopathy — with 75% five-year mortality — produces restrictive physiology, so a right atrial to wedge ratio above 0.5 is part of the diagnostic work-up and may inform a re-transplantation decision.
Left Ventricular Assist Devices
- Candidacy includes a wedge pressure at or above 20 mmHg with a systolic pressure at or below 90 mmHg, or an index at or below 2.0 L/min/m², alongside the other criteria. Before implantation the right atrial pressure should be 12–15 mmHg or lower to minimise right ventricular overload, and the study is done within 1–2 weeks of elective surgery or pre-operatively in intensive care. (sources/rhc-hf-ehj-2025, rating: high)
- Right ventricular failure after implantation is predicted by a right atrial pressure above 15 mmHg with a ratio to wedge above 0.63 — one-year survival 59% against 78% — and by a pulsatility index below 1.85, which reaches 95% sensitivity. (sources/rhc-hf-ehj-2025)
- Speed optimisation and recovery assessment are mirror-image studies with different targets.
| Parameter | Forward ramp (speed optimisation) | Reverse ramp (recovery assessment) |
|---|---|---|
| Right atrial pressure | <12 mmHg | <10 mmHg |
| Wedge pressure | <18 mmHg | ≤12–15 mmHg |
| Cardiac index | >2.2 L/min/m² | ≥2.4–2.6 L/min/m² |
| Mean arterial pressure | — | ≥65 mmHg |
| Additional finding | Intermittent aortic valve opening; minimal mitral regurgitation | Stable or rising pulse pressure, or persistently low wedge, at nominal speed predicts sustained recovery |
(sources/hemodynamic-hf-pht-aha-2026, rating: very high; sources/rhc-hf-ehj-2025, rating: high)
- A forward ramp combines echocardiography with invasive haemodynamics at varying speeds, detects pump thrombosis and is associated with fewer readmissions and haemocompatibility events. Thermodilution output is preferred to estimated Fick in these patients.
- Explantation for myocardial recovery (Class 2a) requires an index above 2.6 L/min/m², right atrial pressure below 10 mmHg and wedge below 13 mmHg, confirmed across serial speed reductions and off-pump trials.
Portal Hypertension and High-Output Failure
- Distinguish hepatic congestion from intrinsic liver disease before LVAD or transplantation, because the second may disqualify the patient. Measure the hepatic vein wedge pressure: a gradient of 1–5 mmHg from hepatic vein to wedge is normal, and portal hypertension is suspected above 5 mmHg. An elevated hepatic vein pressure with a normal gradient points to congestion rather than intrinsic disease. (sources/rhc-hf-jacchf-2024, rating: high)
- High-output heart failure is heart failure with an index above 4.0 L/min/m², and is uncommon. Obesity, liver disease and arteriovenous fistulae lead the causes; a fistula raises venous return and output while lowering systemic resistance, and over time produces heart failure, right ventricular failure and pulmonary hypertension. Catheterise at baseline and repeat after one minute of fistula compression — a manoeuvre shown to be safe — although whether the response predicts long-term improvement after fistula modification is unknown. Takedown can produce reverse remodelling. (sources/rhc-hf-jacchf-2024)
Remote Pressure Monitoring
- Implantable pulmonary artery pressure monitoring is recommended for NYHA II–III heart failure with recent hospitalisation or raised natriuretic peptides. CHAMPION (CardioMEMS) reduced heart failure hospitalisations and urgent visits; GUIDE-HF and MONITOR-HF reproduced the hospitalisation reduction across ejection fractions; PROACTIVE-HF (Cordella) showed significant reductions and confirmed the safety of seated pressure measurement. (sources/hemodynamic-hf-pht-aha-2026, rating: very high)
- Rising pressures are detected days to weeks before clinical congestion, which allows diuretic titration and guideline-directed therapy to be adjusted in advance. Data in pulmonary arterial hypertension specifically remain limited.
Non-Invasive Alternatives
- Candidate replacements for the wedge pressure are all promising and none is established: four-dimensional flow cardiac magnetic resonance, where left atrial flow acceleration correlates with invasive wedge pressure (r = 0.94, standard deviation of differences 2 mmHg); lung ultrasound B-lines, with an area under the curve of 0.73 for a wedge above 15, specific only at a high B-line index; left atrial strain, with an area under the curve of 0.9 at rest or exercise; and a combined mitral deceleration, isovolumetric relaxation and pulmonary venous flow formula (area under the curve 0.91). (sources/rhc-hf-ehj-2025, rating: high)
Contradictions / Open Questions
- ESC and AHA disagree on whether routine catheterisation helps in chronic heart failure. ESC allows it as Class 2b in selected patients; AHA makes routine use Class 3. The divergence reflects different readings of the same observational evidence rather than conflicting data, and it means the same patient is a reasonable candidate in one system and an unjustified procedure in the other. (sources/rhc-hf-ehj-2025, rating: high)
- Early catheterisation in cardiogenic shock rests on observation alone. The association with less kidney injury and more mechanical support comes from a 46,963-patient cohort, not a trial; the randomised comparison is still running. (sources/rhc-hf-ehj-2025)
- The acute heart failure tables use two wedge boundaries that overlap. Diamond–Forrester splits wet from dry at 18 mmHg while the phenotype table splits at 15; and within that table isolated right ventricular failure is defined as a wedge below 18 against biventricular failure above 15. A wedge of 16 mmHg therefore supports two labels. Both come from the source and neither is reconciled there.
- The LVAD right ventricular failure predictors contradict each other. One paragraph states that a pulsatility index below 1.85 outperforms right atrial pressure, the ratio and stroke work index; the next states that stroke work index and right atrial pressure are the best parameters for the same outcome. No study compares them head-to-head in the same cohort. (sources/rhc-hf-ehj-2025)
- Vasodilator testing before transplantation predicts a number, not a survival benefit. One American study found no survival advantage despite resistance falling below 2.5 WU; another found improved survival. No absolute resistance cut-off is endorsed by current guidelines. (sources/rhc-hf-ehj-2025)
- Remote pressure monitoring has better trial evidence than its guideline class. CHAMPION, GUIDE-HF, MONITOR-HF and PROACTIVE-HF all show hospitalisation reduction, while ESC grades the strategy 2b and AHA declines routine right heart catheterisation — a device that is proven to change management sits at a lower recommendation level than the measurement it replaces. (sources/hemodynamic-hf-pht-aha-2026, rating: very high; sources/rhc-hf-ehj-2025)
Connections
- Part of concepts/Right-Heart-Catheterization — the parent overview
- concepts/RHC-Technique-and-Measurement — how the numbers are obtained
- concepts/RHC-Haemodynamic-Interpretation — thresholds and provocation
- entities/Heart-Failure — the syndrome these measurements describe
- entities/HFpEF — preserved ejection fraction and the exercise criteria
- concepts/Cardiogenic-Shock — SCAI staging, support and weaning
- concepts/Pulmonary-Hypertension — classification and treatment arms
- concepts/Constrictive-vs-Restrictive — the differentiation the ratio begins
- concepts/Right-Ventricular-Failure — the chamber that decides transplant and LVAD candidacy
- concepts/Aortic-Stenosis and concepts/Primary-Mitral-Regurgitation — valve lesions where the catheter arbitrates
- concepts/Cardiorenal-Syndrome — congestion and renal function